Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.7744 ^USD	-1.20%		-3.20%	-12.89%

Apr. 05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT
Apr. 05	Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	MT

Achilles Therapeutics : Cell Therapy Potency Assay Summit

July 24, 2022

Strategies for Developing a Potency Assay for a Clonal Neoantigen-Reactive Cell Therapy Product

Carolyn Edwards Director, Research Programs, Achilles Therapeutics

Synopsis

• Showcasing options for measuring potency effectively
• Discussing data generation in Phase I trials
• Transition from early stage to late-stage development for potency assays
• Supporting characterization and development by designing phase appropriate potency assay

Attachments

Original Link
Original Document
Permalink

Disclaimer

Achilles Therapeutics plc published this content on 25 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 18:37:03 UTC.

Latest news about Achilles Therapeutics plc

Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	Apr. 05	MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	Apr. 05	MT
ADRs Close Lower; Moatable Inc. Declines 33.3%	Apr. 04	DJ
Syncona notes investee Achilles's annual loss narrows	Apr. 04	AN
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	Apr. 04	CI
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	Dec. 14	MT
Syncona notes investee company's quarterly loss	Nov. 14	AN
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Syncona's portfolio Achilles Therapeutics net loss narrows	23-08-04	AN
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Uncertain Investor Sentiment Weighs on American Depositary Receipts of European Equities	23-06-09	MT
Chardan Trims Price Target on Achilles Therapeutics to $11 From $12, Keeps Buy Rating	23-05-11	MT
Syncona say portfolio clinical company Achilles have widened losses	23-05-10	AN
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Achilles Therapeutics plc Announces New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies Most Potent T Cell Antigens	23-05-10	CI
Achilles Therapeutics Receives Non-Compliance Notice From Nasdaq	23-04-26	MT
Biotech, Natural Resources Lead European Equities Lower in Wednesday Trading	23-04-19	MT
Bank Stock Recovery Supports American Depositary Receipts of European Equities	23-03-27	MT
Chardan Adjusts Price Target on Achilles Therapeutics to $12 From $17, Keeps Buy Rating	23-03-08	MT
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-07	CI
China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook Weighs	22-12-28	MT
Achilles Therapeutics plc(NasdaqGS:ACHL) dropped from NASDAQ Biotechnology Index	22-12-16	CI
Oppenheimer Downgrades Achilles Therapeutics to Perform From Outperform on Lack of Clear Benefits to Cancer Drug Over Peer Treatment, Removes PT From $19	22-12-07	MT

Chart Achilles Therapeutics plc

Duration

Period

More charts

Company Profile

Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Chardan Cell Therapy Manufacturing Summit

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7744 USD

Average target price

4.125 USD

Spread / Average Target

+432.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACHILLES THERAPEUTICS PLC	-12.89%	31.81M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.53%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research